For the year ending 2025-12-31, ACA had $27,300K increase in cash & cash equivalents over the period. $175,500K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 208,400 |
| Depreciation, depletion, and amortization | 223,000 |
| Impairment charge | 1,600 |
| Stock-based compensation expense | 26,400 |
| Gain on disposition of assets and sale of businesses | 3,400 |
| Provision for deferred income taxes | 26,000 |
| (increase) decrease in other assets | -2,900 |
| Increase (decrease) in other liabilities | -2,600 |
| Other | -13,300 |
| (increase) decrease in receivables | 69,500 |
| (increase) decrease in inventories | 72,600 |
| (increase) decrease in other current assets | -6,400 |
| Increase (decrease) in accounts payable | 21,900 |
| Increase (decrease) in advance billings | -43,200 |
| Increase (decrease) in accrued liabilities | 2,500 |
| Net cash provided by operating activities | 341,100 |
| Proceeds from disposition of assets | 26,600 |
| Proceeds from sale of businesses | 0 |
| Capital expenditures | 165,600 |
| Cash received (paid) for acquisitions | -17,600 |
| Net cash required by investing activities | -121,400 |
| Payments to retire debt | 168,700 |
| Proceeds from issuance of debt | 0 |
| Shares repurchased | 0 |
| Dividends paid to common shareholders | 10,000 |
| Purchase of shares to satisfy employee tax on vested stock | 12,900 |
| Holdback payment from acquisition | 0 |
| Debt issuance costs | 800 |
| Net cash (required) provided by financing activities | -192,400 |
| Net increase (decrease) in cash and cash equivalents | 27,300 |
| Cash and cash equivalents at beginning of period | 187,300 |
| Cash and cash equivalents at end of period | 214,600 |
Arcosa, Inc. (ACA)
Arcosa, Inc. (ACA)